Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
hoping for positive news for sure... something BIG is coming IMHO!!
* * $TRXC Video Chart 07-29-2020 * *
Link to Video - click here to watch the technical chart video
Nice action today...could we get positive news prior to earnings? This maker of surgical robots and medical instruments is expected to post quarterly loss of $0.38 per share in its upcoming report, which represents a year-over-year change of +67.5%.
;) moving from recovery phase into a run. GL everyone! Boom time a comin.
* * $TRXC Video Chart 07-28-2020 * *
Link to Video - click here to watch the technical chart video
* * $TRXC Video Chart 07-21-2020 * *
Link to Video - click here to watch the technical chart video
T R X C finally moving up in power hour. If we are lucky it will close HOD.
This was supposed to go higher every time ISRG went higher. Instead, ISRG - which BENEFITS from coronavirus- as does every other biotech company in the world- EXCEPT for pathetic TRXC- is now at $650 and the world's worst stock is sitting at 33 cents- after reverse splitting a million times. The mgmt team for $TRXC should all be shot with covid19- with no vaccine and no cure and left for dead relying only on their own useless drugs for survival.
* * $TRXC Video Chart 07-08-2020 * *
Link to Video - click here to watch the technical chart video
Insider bought investment co bought 8 steak let’s go chart ready to rump plus dd adds up
* * $TRXC Video Chart 07-07-2020 * *
Link to Video - click here to watch the technical chart video
* * $TRXC Video Chart 07-01-2020 * *
Link to Video - click here to watch the technical chart video
what's going on today.. going to open up 7% up!!...
Why did you ask the question in your post if you didn't want the answer?
completely agree... posting news from 6 months ago like it was just announced is B.S.!!!
Daudah and Domino. You two will be reported for citing news that was made in 2019. Are you guys living in the past?
13:1? Says who? you? Where's the news about this?
If you think .95 is making $$$ after a 13:1 RS? You are.
0.9765 ? 0.1564 (19.07%)
Volume: 12,426,411 @06/09/20 12:53:36
* * $TRXC Video Chart 06-04-2020 * *
Link to Video - click here to watch the technical chart video
And yet, we're making money on it.
@ Domino: Who's the uneducated now? Last laugh laughs the loudest!!
Good action here. What a gap to potentially fill.
Are the uneducated still pumping this garbage?
FDA this, FDA that. Get this through your heads......
THE PLATFORM IS NOT VIABLE. This isn’t opinion, it’s based on clinical studies.
TRXC knows it, their own surgeons alluded to it as well. The only reason they’ve submitted anymore for appointments is for a pump to further fleece uneducated retail investors.
2020-03-06 13G 89366M300 / TransEnterix Inc 4,378,417
check out all the companies they recently they bought discounted shares in
a whole gamut of bio's in the CV arena, pretty smart on their part
as they sell into the rallies
https://fintel.io/i/sabby-management-llc
* * $TRXC Video Chart 03-13-2020 * *
Link to Video - click here to watch the technical chart video
Everything getting beating down shitty market ~
Possible short term target of 60 cents.
TRXC .40 only up small on intriguing NEWS
TransEnterix Receives FDA Clearance for First Machine Vision System in Robotic Surgery
https://finance.yahoo.com/news/transenterix-receives-fda-clearance-first-105500629.html?.tsrc=rss
This will get pumped Monday AH
$TRXC: Took a hit......... oh well
Can't win them all.
Still operating at 80% track record
Made up more than enough on Put options place in the past 2wks
That is a clueless post Sport 19 is not a fan of Titan quite the opposite IMO.
But he is correct about the turd regardless.
It’s too late for this piece of garbage
Did anyone say it isn’t safe? It’s a colossal failure with a colossal footprint....
This will do nothing to move the needle...
* * $TRXC Video Chart 02-12-2020 * *
Link to Video - click here to watch the technical chart video
$TRXC: NEWS.......... CE-Mark-Approval for Pediatric-Indication for Senhance
PEDIATRIC !!!!!!!!!!!!!!!!!
How safe is THAT ??????????
Bloody hell........... this thing is GOOD !
GO $TRXC
*********************************************************************
TransEnterix Announces CE Mark Approval for Pediatric Indication for Senhance Surgical System
6:50 AM ET 2/12/20 | BusinessWire
Related Quotes
8:00 PM ET 2/11/20
Symbol Last % Chg
TRXC
1.22 0.00%
Real time quote.
TransEnterix is First to Offer Robotic 3 mm Microlaparoscopic Surgery for Pediatric Patients
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--February 12, 2020--
TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that the Company received CE Mark approval for an expanded indication to treat pediatric patients above 10kg (approximately 22 lbs) with the Senhance(R) System.
"Given the size of the patients, pediatric surgery seeks to use the smallest instruments and scopes possible to minimize invasiveness, yet it is critical to maintain a high degree of precision," said Anthony Fernando, president and chief executive officer of TransEnterix. "The Senhance System is designed to maximize control of instruments as small as 3 mm and be compatible with small scopes while also retaining the sense of touch through haptic feedback. This makes our technology uniquely positioned to meet the requirements of pediatric surgeons, and we look forward to working closely with leading European hospitals to serve the needs of their pediatric patients."
"The ability to use 3 mm microlaparoscopic instruments on a robotic platform is very exciting and is a large step forward in treating pediatric patients," said Prof. Dr. Wim van Gemert, chairman of the department of pediatric surgery, Maastricht University Medical Center+ in the Netherlands. "Especially in younger patients, smaller ports and instruments are critically important in achieving the best outcomes given the body size constraints in these patients."
The Senhance(R) Surgical System is the first and only digital laparoscopic platform designed to maintain laparoscopic MIS standards while providing digital benefits such as haptic feedback, robotic precision, eye-sensing camera control, comfortable ergonomics, advanced instrumentation including, 3 mm microlaparoscopic instruments, eye-sensing camera control and reusable standard instruments to help maintaining per-procedure costs similar to traditional laparoscopy.
Senhance European Indication for Use
The Senhance(R) Surgical System has received a CE Mark according to the Medical Device Directive and is intended to be used for laparoscopic surgery in the abdomen, pelvis and limited uses in the thoracic cavity excluding the heart and greater vessels. The system is indicated for adult and pediatric use in CE marked territories.
About TransEnterix
TransEnterix is a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options in today's value-based healthcare environment. The Company is focused on the commercialization of the Senhance Surgical System, which digitizes laparoscopic minimally invasive surgery. The system allows for robotic precision, haptic feedback, surgeon camera control via eye sensing and improved ergonomics while offering responsible economics. The Senhance Surgical System is available for sale in the US, the EU, Japan and select other countries. For more information, visit www.transenterix.com.
Forward-Looking Statements
This press release includes statements relating to the Senhance System and the expansion of indications to include pediatric applications in CE marked territories. These statements and other statements regarding our future plans and goals constitute "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations, including whether the indication expansion to treat pediatric patients will broaden our Senhance footprint in CE countries and whether the Senhance System technology is uniquely positioned to meet the requirement of pediatric surgeons. For a discussion of the risks and uncertainties associated with TransEnterix's business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on February 27, 2019 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200212005171/en/
CONTACT: Investor Contact:
Mark Klausner, +1 443-213-0501
invest@transenterix.com
or
Media Contact:
Terri Clevenger, +1 203-682-8297
terri.clevenger@icrinc.com
SOURCE: TransEnterix, Inc.
Copyright Business Wire 2020
> Dow Jones Newswires
February 12, 2020 06:50 ET (11:50 GMT)
$TRXC: NEWS....... Senhance in JAPAN
UP in AfterHours.
GO $TRXC
********************************************************
TransEnterix Announces Kitakyushu General Hospital in Japan to Initiate a Senhance Digital Laparoscopy Program
4:05 PM ET 1/29/20 | BusinessWire
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--January 29, 2020--
TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that the Kitakyushu General Hospital, a hospital in southwestern Japan, has entered into an agreement to lease and utilize a Senhance(R) System.
"We are excited to partner with Kitakyushu General Hospital to build its Senhance Digital Laparoscopy Program," said Anthony Fernando, president and chief executive officer at TransEnterix. "We believe the Senhance System, with its digital laparoscopic interface and responsible economics, is a great fit for the Japanese market. With our first system at Saitama Medical University and now a second system with Kitakyushu General Hospital, we are building the foundation for future Senhance success in Japan."
Kitakyushu General Hospital is a prestigious institution and is recognized as one of the major hospitals in Kitakyushu. It offers both advanced and emergency medical care and is a core part of the Kitakyushu Hospital Group. It is a 360-bed facility that contains a critical care center and is the only general hospital in the Kitakyushu Hospital Group.
"Improving patient care through innovative technologies is important to our hospital," said Dr. Naoki Nagata, President of Kitakyushu General Hospital. "Senhance will be a welcome addition to our minimally invasive surgery program, leveraging our existing laparoscopic skill sets, enabling maximum precision, visualization and control during delicate surgeries and doing so with cost-effective technology, which addresses the need to minimize healthcare costs."
The Senhance(R) Surgical System is the first and only digital laparoscopic platform designed to maintain laparoscopic MIS standards while providing digital benefits such as haptic feedback, robotic precision, eye-sensing camera control, comfortable ergonomics, advanced instrumentation including, 3 mm microlaparoscopic instruments, eye-sensing camera control and reusable standard instruments to help maintaining per-procedure costs similar to traditional laparoscopy.
The Senhance Surgical System was approved for use by the Japanese Ministry of Health, Labor and Welfare (MHLW) in 2019, and has the broadest procedural reimbursement of any abdominal robotic surgery platform in Japan, which applies to 98 benign and malignant laparoscopic procedures across general, colorectal, gynecologic, pediatric and urologic surgeries at reimbursement rates equivalent to traditional laparoscopy in Category A1.
Japan is the second-largest medical device market in the world, valued at over $40 billion annually, including over $5 billion in capital equipment spending. There are more than 8,400 hospitals in Japan, of which approximately 80% are private entities. Japanese laparoscopic penetration in surgery is among the highest in the world. The central government has implemented cost containment initiatives in recent years and has approached recent procedure approvals for robotics by establishing reimbursement at the same rate as traditional laparoscopy, which places a high emphasis on procedure cost to influence adoption.
About TransEnterix
TransEnterix is a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options in today's value-based healthcare environment. The Company is focused on the commercialization of the Senhance Surgical System, which digitizes laparoscopic minimally invasive surgery. The system allows for robotic precision, haptic feedback, surgeon camera control via eye sensing and improved ergonomics while offering responsible economics. The Senhance Surgical System is available for sale in the US, the EU, Japan and select other countries. For more information, visit www.transenterix.com.
Forward-Looking Statements
This press release includes statements relating to the Senhance System and the Kitakyushu General Hospital initiating a program with the Senhance System. These statements and other statements regarding our future plans and goals constitute "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations and include whether the Senhance System, with its digital laparoscopic interface and responsible economics, will be a great fit for the Japanese market, and whether the placement of a Senhance System with Kitakyushu General Hospital, following a placement at Saitama Medical University, will build a foundation for future Senhance success in Japan. For a discussion of the risks and uncertainties associated with TransEnterix's business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on February 27, 2019 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200129005659/en/
CONTACT: For TransEnterix, Inc.
Investor Contact:
Mark Klausner, +1 443-213-0501
invest@transenterix.com
or
Media Contact:
Terri Clevenger, +1 203-682-8297
terri.clevenger@icrinc.com
SOURCE: TransEnterix, Inc.
Copyright Business Wire 2020
> Dow Jones Newswires
January 29, 2020 16:05 ET (21:05 GMT)
Your wasting your time.....this was over years ago....
Hilarious!
What year is it.....?????
LOL
Followers
|
178
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
7900
|
Created
|
10/20/08
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |